N-{3-[1-(5-aminopentyl)piperidin-4-yl]phenyl}isobutyramide | 486449-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-{3-[1-(5-aminopentyl)piperidin-4-yl]phenyl}isobutyramide
• 英文别名: N-{3-[1-(5-aminopentyl)-4-piperidinyl]phenyl}-2-methylpropanamide；N-[3-[1-(5-aminopentyl)piperidin-4-yl]phenyl]-2-methylpropanamide
• CAS: 486449-04-1
• 化学式: C₂₀H₃₃N₃O
• 分子量: 331.502
• InChiKey: JBTKHXRZDVHYDG-UHFFFAOYSA-N

物化性质

• 沸点：
  509.5±50.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-{3-[1-(5-aminopentyl)piperidin-4-yl]phenyl}isobutyramide 、 二苯基乙酰氯 以 Tetrahydrofurane dichloromethane 为溶剂， 生成 N-[3-(1-{5-[(Diphenylacetyl)amino]pentyl}-4-piperidinyl)phenyl]-2-methylpropanamide
  参考文献：
  名称：

  Substituted anilinic piperidines as MCH selective antagonists

  摘要：

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供一种药物组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。本发明提供一种由本发明的化合物的治疗有效量和药学上可接受的载体组合而成的药物组合物。本发明还提供一种制备药物组合物的方法，包括将本发明的化合物的治疗有效量和药学上可接受的载体组合。

  公开号：

  US06727264B1
• 作为产物：
  描述：

  N-(3-piperidin-4-ylphenyl)isobutyramide 在 四丁基碘化铵 、 一水合肼 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 4.0h， 生成 N-{3-[1-(5-aminopentyl)piperidin-4-yl]phenyl}isobutyramide
  参考文献：
  名称：

  Synthesis and SAR Investigations for Novel Melanin-Concentrating Hormone 1 Receptor (MCH₁) Antagonists Part 1. The Discovery of Arylacetamides as Viable Replacements for the Dihydropyrimidinone Moiety of an HTS Hit

  摘要：

  Melanin-concentrating hormone (MCH) is involved in the regulation of feeding, water balance, energy metabolism, general arousal and attention state, memory, cognitive functions, and psychiatric disorders. Herein, two new chemical series exemplified by N-[5-(1-{3-[2,2-bis-(4-fluoro-phenyl)-acetylamino]-propyl}-piperidin-4-yl)-2,4-difluoro-phenyl]-isobutyramide (SNAP 102739, 5m) and N-[3-(l-{3-[(S)-2-(4-fluorophenyl)-propionylamino]-propyl}-piperidin-4-yl)-4-methylphenyl]-isobutyramide ((S)-6b) are reported. These compounds were designed to improve the pharmacokinetic properties of the high-throughput screening lead compound 1 (SNAP 7941). The MCH, receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively). Compounds 5m and (S)-6b demonstrated the inhibition of a centrally administered MCH-evoked drinking effect, and compound 5m exhibited oral in vivo efficacy in the rat social interaction model of anxiety, with a minimum effective dose = 0.3 mg/kg.

  DOI：

  10.1021/jm060381c

文献信息

• Substituted alkyl amido piperidines
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040186103A1

  公开（公告）日：2004-09-23

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。该发明提供了一种包含本发明化合物的治疗有效量和药学可接受载体的制药组合物。本发明提供了一种由本发明化合物的治疗有效量和药学可接受载体组合而成的制药组合物。本发明还提供了一种制备包括本发明化合物的治疗有效量和药学可接受载体的制药组合物的方法。本发明还提供了一种减轻受试者身体质量的方法，该方法包括向受试者投与本发明化合物的有效量，以减轻受试者的身体质量。本发明还提供了一种治疗患有抑郁和/或焦虑症的受试者的方法，该方法包括向受试者投与本发明化合物的有效量，以治疗受试者的抑郁和/或焦虑症。
• SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
  申请人：Synaptic Pharmaceutical Corporation

  公开号：EP1411942A1

  公开（公告）日：2004-04-28
• EP1411942A4
  申请人：——

  公开号：EP1411942A4

  公开（公告）日：2005-01-26
• US6727264B1
  申请人：——

  公开号：US6727264B1

  公开（公告）日：2004-04-27
• US7067534B1
  申请人：——

  公开号：US7067534B1

  公开（公告）日：2006-06-27